Vadodara-based bio-manufacturing startup Genexis Biotech has raised ₹4 crore in a seed funding round led by GVFL, with participation from Benzai10. The company is focused on transforming biotech manufacturing through sustainable, precision-based innovation.
Genexis aims to scale the production of animal-origin-free recombinant proteins using precision fermentation — offering ethical and scalable biomolecule solutions for sectors like biopharma, food-tech, and cell culture.
The capital raised will support expansion of infrastructure, product development, and regulatory strength.
Founded in 2019 by Vipul Kumar and Jitendra Wagh, Genexis Biotech was built on the belief that India can lead the shift towards sustainable, high-quality bio-manufacturing. The company is headquartered in Vadodara and operates a certified Class 10,000 facility with plans for a GMP-compliant unit.
Also Read | EVeez Raises $5.4 Mn in Series A Funding Led by Michael & Susan Dell Foundation
With the new funds, Genexis will expand its bioreactor capacity, build downstream processing infrastructure, and launch new recombinant proteins such as transferrin and albumin. It will also focus on strengthening sales, distribution, and regulatory compliance.
In the past year, the startup has introduced recombinant peptidases like amino peptidase and enterokinase, partnered with pharmaceutical and biotech companies, and signed an MoU with the Gujarat government. It also showcased its innovation portfolio at Global Bio-India 2024 and has received multiple orders for alternative protein formulation projects.
Looking ahead, Genexis plans to enter the regulated biotech export market, collaborate with CDMOs, academic labs, and biopharma firms, and develop encapsulated growth factor formulations for the cosmetics industry.
